Company profiles focus on technology, evidence and scientific position. We do not value companies or rate them as investments.
Cellular reprogramming
Research-first company pursuing partial epigenetic reprogramming to restore cell health and function. Heavily funded, deliberately pre-clinical, and publishing in the open literature rather than racing to a single asset.
Cellular reprogramming, autophagy
Focused company targeting ten additional years of healthy human lifespan through reprogramming, plasma-inspired interventions and autophagy restoration.
Senolytics
Clinical-stage company developing medicines that selectively clear senescent cells, historically focused on ophthalmology and localized delivery.
Immune-mediated senescent cell clearance
Develops small molecules that recruit the innate immune system to clear senescent cells rather than killing them directly.
Selective senolytic prodrugs
Uses a chemistry platform to design prodrugs activated inside senescent cells, aiming for tissue-selective clearance.
In vivo CRISPR gene editing
Clinical-stage genome editing company with in vivo CRISPR programmes in amyloidosis and hereditary angioedema.
Base editing
Precision genetic medicine company using base editing to make single-letter DNA changes without double-strand breaks.
Partial epigenetic reprogramming (OSK)
Advancing partial reprogramming toward the clinic with an initial focus on optic neuropathy.
Computational reprogramming discovery
Uses virtual cell models to search for reprogramming factor sets that rejuvenate cells without erasing identity.
Generative AI drug discovery
Generative chemistry and target discovery company with clinical assets originating from its AI platform.
Phenomics + ML drug discovery
Industrial-scale cellular imaging paired with machine learning to map biology and generate candidates.
NAD+ precursors
Developing pharmaceutical-grade NAD+ precursors intended to be tested as drugs rather than supplements.
Nicotinamide riboside (consumer NAD+)
Consumer-facing NAD+ precursor business with an associated clinical research programme.
Alternative splicing / stem cell modulation
Targets splicing regulation to influence progenitor cell behaviour, with lead work in osteoarthritis.
iPSC-derived cell therapy
Engineered cell therapies derived from induced pluripotent stem cells, with a lead Parkinson's programme.
mTOR inhibition / immune aging
Developing selective TORC1 inhibitors intended to improve immune function in older adults.
Immune secretome therapy
Develops an immune-modulating secretome intended to counter age-related muscle and immune decline.
Metabolic health measurement and therapeutics
Combines continuous metabolic measurement with a therapeutics pipeline targeting insulin resistance in aging.
Allogeneic macrophage-reprogramming cell therapy
Clinical-stage company developing Allocetra, an allogeneic cell therapy intended to reprogram macrophages toward immune homeostasis. Company-reported development includes an FDA Regenerative Medicine Advanced Therapy designation in knee osteoarthritis.
Antisense oligonucleotide (ASO)
Neuroscience company developing diranersen (BIIB080 / IONIS-MAPTRx), an antisense oligonucleotide designed to target MAPT mRNA and reduce tau production, evaluated in the Phase 2 CELIA study in early Alzheimer's disease.
Antisense oligonucleotide (ASO)
RNA-targeted medicines company whose antisense platform discovered diranersen (IONIS-MAPTRx / BIIB080), a MAPT-directed antisense oligonucleotide for Alzheimer's disease; Biogen exercised its licence option and holds a worldwide exclusive royalty-bearing licence to develop and commercialise it.
Oligonucleotide Transport Vehicle (OTV), blood-brain barrier delivery
Neurodegeneration company applying its Oligonucleotide Transport Vehicle to cross the blood-brain barrier; DNL628 (OTV:MAPT) is designed to reduce tau through MAPT targeting in Alzheimer's disease.
